Combinational chemotherapy of L1210 and L1210/ARA-C leukemia with 5-AZA-2′-deoxycytidine and β-2′-deoxythioguanosine

✍ Scribed by Richard L. Momparler; Louise F. Momparler; Johanne Samson

• Publisher: John Wiley and Sons
• Year: 1982
• Tongue: French
• Weight: 359 KB
• Volume: 30
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910300317

✦ Synopsis

Abstract

The in vitro and in vivo antineoplastic activity of 5‐AZA‐2'‐deoxycytidine (5‐AZA‐CdR) and β‐2‐deoxythioguanosine (TGdR) on L1210 an L1210/ARA‐C (resistant to cytosine arabinoside) leukemic cells was investigated. 5‐AZA‐CdR was a very potent cytotoxic agent against the L1210 leukemic cells. This analogue was inactive against L1210/ARA‐C leukemic cells because these cells lack deoxycytidine kinase, the enzyme that converts 5‐AZA‐CdR to its active nucleotide form. TGdR was a potent cytotoxic agent to both L1210 and L1210/ARA‐C leukemic cells. In mice which were injected simultaneously with both L1210 and L1210/ARA‐C leukemic cells, the drug combination of 5‐AZA‐CdR plus TGdR had a very potent antineoplastic activity and producet long‐term survivors. Either agent alone did not produce any long‐term survivors in the mice with L1210 and L1210/ARA‐C leukemia. This experimental model indicates that 5‐AZA‐CdR plus TGdR is an interesting drug combination for the treatment of leukemia with drug‐resistant cells.